The CB2 agonists AM1241 and AM1714 Suppress Paclitaxel evoked Mechanical Allodynia In paclitaxel treated subjects, AM1714 and AM1241 suppressed paclitaxel induced mechanical allodynia in accordance with the vehicle condition. Paclitaxel induced mechanical allodynia was maximally suppressed by each agonist at half an hour post injection. As of this time point, both AM1241 and AM1714 normalized thresholds in accordance with prepaclitaxel levels. AM1241 did not induce an effect in animals that received cremophor: ethanol: AG-1478 clinical trial saline vehicle in place of paclitaxel pre procedure compared to. postinjection: 42. 14 0. 36 g versus. 40. 93 0. 78 h, R 0. 32, planned comparison t test. However, AM1714 produced a small antinociceptive result pre treatment versus. post injection: 63. 21 2. 98 g vs. 76. 92 4. 22 gary, R 0. 05, planned assessment t test. Moreover, cremophor therapy did not change day 21 paw withdrawal thresholds in accordance with day 0 baseline paw withdrawal thresholds in just about any class. Standard foot withdrawal thresholds averaged 46 morning 0. 89 4. 23 h and 63. 60 4. 61 g prior to initiation of Skin infection cremophor treatment in groups that subsequently received AM1714 and AM1241, respectively on day 21. A diminished baseline limit was seen in the former set alongside the latter group. Group differences in baseline paw withdrawal thresholds might reflect individual differences combined with the sensitivity of the unit since each animal s patience was highly reliable and reproducible. No differences between day 0 baseline paw withdrawal thresholds were observed for any groups tested from the same experimenter in any given study. Effects of AM1241 and its Enantiomers on Paclitaxel evoked Mechanical Allodynia AM1241 improved technical withdrawal thresholds in a dose related fashion relative to the automobile condition. Both the high and middle doses of AM1241 improved paw withdrawal thresholds relative to vehicle. Effects of the reduced amount of AM1241 didn’t vary from car. Both large and the amounts of AM1241 also raised paw withdrawal thresholds relative to Celecoxib preinjection thresholds decided 21 days following paclitaxel treatment. Neither the lower amount of AM1241 or DMSO improved foot withdrawal thresholds relative to pre shot thresholds evaluated on day 21 post paclitaxel. Although DMSO failed to do so, the center and large doses of AM1241 normalized foot withdrawal thresholds in accordance with baseline thresholds. AM1241 improved paw withdrawal thresholds relative to the vehicle issue in paclitaxel treated groups. AM1241 did not significantly raise foot withdrawal limit relative to car. Nevertheless, post hoc comparisons failed to show differential effects between AM1241 and both AM1241 or AM1241 on paw withdrawal thresholds.